MAIN PROVISIONS OF THE RUSSIAN CONSENSUS ON DIAGNOSIS AND TREATMENT OF AUTOIMMUNE HEPATITIS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the main provisions of the Russian Consensus on the Diagnosis and Treatment of Autoimmune Hepatitis (AIH). The consensus was conducted on the initiative of a group of specialists in the field of hepatology and gastroenterology. Voting was performed according to the Delphic system using the 6-point Likert scale: «1 point» meant «totally agree» (A +), «2» - «agree with small remarks» (A), «3» - «agree with significant comments» (A-), «4» - «disagree, but with significant comments» (D-), «5» - «do not agree, but with small remarks» (D), «6» - «strongly disagree» (D +). The agreement was deemed to have been achieved in agreement with the provision (A+, A, A-) of more than 2/3 experts (i.e. 67% or more). The interdisciplinary approach was provided by participation of leading gastroenterologists, hepatologists, morphologists, and pediatricians. The article is published as part of a series of papers on the main provisions of the Consensus. The purpose of these recommendations is to improve the diagnosis and therapy of AIH in conditions of real clinical practice, to provide timely assistance to this category of patients. Experts of large domestic clinical centers with significant experience in the diagnosis and treatment of AIH participated in the discussion of these recommendations.

Full Text

Restricted Access

About the authors

E. V Vinnitskaya

SBHCI “Moscow Clinical Scientific and Practical Center n.a. A.S. Loginov" of Mosow Healthcare Department

Yu. G Sandler

SBHCI “Moscow Clinical Scientific and Practical Center n.a. A.S. Loginov" of Mosow Healthcare Department

Email: sandleijulia2012@gmail.com

D. T Abdurakhmanov

FSAEI HE “First Moscow State Medical University n.a. I.M. Sechenov" of RMH (Sechenov University)

I. G Bakulin

FSBEI HE “North-Western State Medical University n.a. I.I. Mechnikov" of RMH

E. A Belousova

FCME SBHCI MR MRSRCI n.a. M.F. Vladimirsky

A. O Buyeverov

FSAEI HE “First Moscow State Medical University n.a. I.M. Sechenov" of RMH (Sechenov University)

E. Z Burnevich

FSAEI HE “First Moscow State Medical University n.a. I.M. Sechenov" of RMH (Sechenov University)

R. B Gudkova

SBHCI “Moscow Clinical Scientific and Practical Center n.a. A.S. Loginov" of Mosow Healthcare Department

M. G Efanov

SBHCI “Moscow Clinical Scientific and Practical Center n.a. A.S. Loginov" of Mosow Healthcare Department

E. Yu Eremina

FSBEI HE “Medical Institute of the Mordovia National Research State University n.a. N.P. Ogarev"

T. M Ignatova

FSAEI HE “First Moscow State Medical University n.a. I.M. Sechenov" of RMH (Sechenov University)

L. Yu Ilchenko

FSBEI HE Russian National Scientific Medical University n.a. N.I. Pirogov of RMH

T. N Lopatkina

FSAEI HE “First Moscow State Medical University n.a. I.M. Sechenov" of RMH (Sechenov University)

I. G Nikitin

FSBEI HE Russian National Scientific Medical University n.a. N.I. Pirogov of RMH

M. S Navruzbekov

SBHCI Scientific Research Institute of First Aid n.a.N.V. Sklifosovsky

A. I Parfenov

SBHCI “Moscow Clinical Scientific and Practical Center n.a. A.S. Loginov" of Mosow Healthcare Department

A. I Pavlov

FSBI «The Third Central Military Clinical Hospital n.a. A.A. Vishnevsky» of the Ministry of Defense of the Russian Federation

A. S Potapov

FSAEI HE “First Moscow State Medical University n.a. I.M. Sechenov" of RMH (Sechenov University)

S. D Podymova

SBHCI “Moscow Clinical Scientific and Practical Center n.a. A.S. Loginov" of Mosow Healthcare Department

K. L Raykhelson

FSBEI HE Saint-Petersburg State University of RMH

A. R Reyzis

FBIS Central Research Institute of Epidemiology of Rospotrebnadzor

D. L Rotin

SBHCI “Moscow Clinical Scientific and Practical Center n.a. A.S. Loginov" of Mosow Healthcare Department

R. G Sayfutdinov

Kazan State Medical Academy - Branch of FSBEI FPE Russian Medical Academy of Continuous Professional Education of RMH

V. L Syutkin

SBHCI Scientific Research Institute of First Aid n.a.N.V. Sklifosovsky

T. V Strokova

FSAEI HE “First Moscow State Medical University n.a. I.M. Sechenov" of RMH (Sechenov University)

S. G Khomeriki

SBHCI “Moscow Clinical Scientific and Practical Center n.a. A.S. Loginov" of Mosow Healthcare Department

T. Yu Khaymenova

SBHCI “Moscow Clinical Scientific and Practical Center n.a. A.S. Loginov" of Mosow Healthcare Department

References

  1. Shaneyfelt T.M., Mayo-Smith M.F., Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA. 1999;281:1900-905.
  2. Czaja A.J. Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Gut and Liver. 2016;10(2):177-203. http://www.gutnliver.org/journal/view. html?uid=809&vmd=Full#T6.
  3. Ивашкин В.Т., Буеверов А.О. Аутоиммунные заболевания печени в практике клинициста. 2-е изд. М., 2011.
  4. Liberal R., Vergani D., Mieli-Vergani G. Update on autoimmune hepatitis. J. Clin. Transl. Hepatol. 2015;3(1):42-52.
  5. Mendizabal M., Marciano S., Videla M.G., et al. Fulminant presentation of autoimmune hepatitis: clinical features and early predictors of corticosteroid treatment failure. Eur. J. Gastroenterol. Hepatol. 2015;27:644-48.
  6. Gassert D.J., Garcia H., Tanaka K., Reinus J.F. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig. Dis. Sci. 2007;52:2433-37.
  7. Буеверов А.О. Серонегативный аутоиммуный гепатит. Рос. журн. гастроэнтерологии гепатологии, колопроктологии. 2017;27(2):27-3.
  8. Yilmaz B., Unlud O., Evcenb R., Ugurluogluc C. Acute onset seronegative autoimmune hepatitis: are simplified diagnostic criteria sufficient? Eur. J. Gastroenterol. Hepatol. 2016;28(5):607-8.
  9. Gleeson D., Heneghan M.A. British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60:1611-29.
  10. Manns M.P., Czaja A.J., Gorham J.D., Krawitt E.L., Mieli-Vergani G., Vergani D., Vierling J.M. Diagnosis and Management of Autoimmune Hepatitis. AASLD Practice Guidelines. Hepatology. 2010;51(6):2193-213.
  11. Gleeson D., Heneghan M.A. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60:1611-29.
  12. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J. Hepatol. 2015;63:971-1004.
  13. Tannapfel A., Dienes H.P., Lohse A.W. The indications for liver biopsy. Dtsch. Arztebl. Int. 2012;109(27-28):477-83.
  14. Johnson P.J., McFarlane I.G. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993;18:998-1005.
  15. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 1999;31(5):929-38.
  16. Hennes E.M., Zeniya M., Czaja A.J., Pares A., Dalekos G.N., Krawitt E.L., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169-76.
  17. Lamers M.M., van Oijen M.G., Pronk M., Drenth J.P Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J. Hepatol. 2010;53(1):191-98.
  18. Czaja A.J. Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol. 2010;16(8):934-47. Published online 2010 Feb 28.
  19. Selvarajah V., Montano-loza A.J., Czaja A.J. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Alimentary pharmacology and therapeutics. 2012;36(8):691-707.
  20. Sebode M., Schramm C. AIH: Which Alternative for Difficult-to-Treat Patients? Dig. Dis. 2015;33(Suppl. 2):83-7.
  21. Parker R., Oo Y.H., Adams D.H. Management of patients with difficult autoimmune hepatitis. Therap. Adv. Gastroenterol. 2012;5(6):421-37.
  22. Czaja A.J. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J. Hepatol. 2009;51:161-67.
  23. Dhaliwal H., McFarlane E., Gleeson D., Lennard L. PTU-108 Azathioprine Pharmacogenetics in Autoimmune Hepatitis. Gut. BMJ. 2012;62(Suppl. 1).
  24. Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy. Gastroenterology. 2004;127(5):1558-64.
  25. Yeoman A.D., Westbrook R.H., Zen Y., et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J. Hepatol. 2014;61:876.
  26. Hviid A., Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. Canadian Medical Association or its licensors. 2011;183(7):796-804.
  27. Werner M., Bjornsson E., Prytz H., Lindgren S., Almer S., Broome U., et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand. J. Gastroenterol. 2007;42(8):986-91.
  28. Terrabuio D.R., Abrantes-Lemos C.P., Carrilho F.J., Cancado E.L. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J. Clin. Gastroenterol. 2009;43(4):350-56.
  29. Westbrook R.H., Yeoman A.D., Kriese S., Heneghan M.A. Outcomes of pregnancy in women with autoimmune hepatitis. J. Autoimmun. 2012;38: 239-44.
  30. Akbari M., Shah S., Velayos F.S., Mahadevan U., Cheifetz A.S. Systematic review and metaanalysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm. Bowel. Dis. 2013;19:15-22.
  31. Westbrook R.H., Yeoman A.D., Kriese S. Outcomes of pregnancy in women with autoimmune hepatitis. J. Autoimmun. 2012;38(2-3):239-44.
  32. de Meij T.G., Jharap B., Kneepkens C.M. Longterm follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. Dutch Initiative on Crohn and Colitis. Aliment. Pharmacol. Ther. 2013;38(1):38-43.
  33. Chen J., Eslick G.D., Weltman M. Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly. Aliment. Pharmacol. Ther. 2014;39(2):117-24.
  34. Muratori P., Lalanne C., Barbato E., Fabbri A., Cassani F., Lenzi M., Muratori L. Features and Progression of Asymptomatic Autoimmune Hepatitis in Italy. Clinical. Gastroenterol. Hepatol. 2016;14-1;139-46.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies